KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Net Margin (2016 - 2025)

Jazz Pharmaceuticals has reported Net Margin over the past 15 years, most recently at 16.98% for Q4 2025.

  • Quarterly Net Margin fell 58.0% to 16.98% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 7.82% through Dec 2025, down 2163.0% year-over-year, with the annual reading at 8.33% for FY2025, 2214.0% down from the prior year.
  • Net Margin was 16.98% for Q4 2025 at Jazz Pharmaceuticals, down from 22.33% in the prior quarter.
  • Over five years, Net Margin peaked at 22.33% in Q3 2025 and troughed at 68.7% in Q2 2025.
  • The 5-year median for Net Margin is 7.89% (2023), against an average of 0.34%.
  • Biggest five-year swings in Net Margin: surged 5249bps in 2022 and later tumbled -8517bps in 2025.
  • Tracing JAZZ's Net Margin over 5 years: stood at 3.61% in 2021, then plummeted by -584bps to 24.69% in 2022, then skyrocketed by 138bps to 9.35% in 2023, then soared by 88bps to 17.56% in 2024, then decreased by -3bps to 16.98% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 16.98%, 22.33%, and 68.7% for Q4 2025, Q3 2025, and Q2 2025 respectively.